Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Cancer MedicineJun 6, 2026
The Steroidal Profile Modulates Adaptive Immune Response and Prognosis in Adrenocortical Carcinoma: Analysis of TCR and BCR Repertoires

Clinical Context

We think this has broad domain relevance to EAU NMIBC Risk Classification.

CancerJun 5, 2026
Correction to “Clinical, genetic, and familial features of POT1 tumor predisposition syndrome”

Clinical Context

We think this has broad domain relevance to EAU NMIBC Risk Classification.

DiabetologiaJun 5, 2026
Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

Clinical Context

We think this has broad domain relevance to EAU NMIBC Risk Classification.

EAU NMIBC Risk

EAU NMIBCRisk Stratification for Bladder Cancer

Prognostic Grouping

Note: Risk is based on the 2021 EAU criteria which considers tumor stage (Ta vs T1), grade (G1-G3/LG vs HG), number of tumors, and concomitant CIS.

Risk Profile

Low

Management Outlook

Low risk group. Single, primary, low-grade Ta tumor < 3 cm. Surveillance only is typically recommended.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Patients with biopsy-proven Ta, T1, or CIS bladder cancer.
To determine the schedule for intravesical therapy (e.g., BCG or Mitomycin C).
To identify "Very High Risk" candidates for early radical cystectomy.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the EAU NMIBC Risk, ISUP Grade Groups or the CTCAE v5.0 to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

EAU NMIBC Risk
ISUP Grade Groups
CTCAE v5.0
ECOG Performance Status
SINS Score
SLiM-CRAB Criteria
SAVER Score
Lugano Classification
RECIST 1.1
Calvert Formula
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.